Open AccessAdiponectin Paradox as a Therapeutic Target in Alzheimer’s Disease
Author(s) -
Masaaki Waragai,
Gilbert Ho,
Yoshiki Takamatsu,
Ryoko Wada,
Shuei Sugama,
Takato Takenouchi,
Eliezer Masliah,
Makoto Hashimoto
Publication year - 2020
Publication title -
journal of alzheimer's disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.677
H-Index - 139
eISSN - 1875-8908
pISSN - 1387-2877
DOI - 10.3233/jad-200416
Subject(s) - disease , medicine , clinical trial , neurotoxicity , adiponectin , immunotherapy , therapeutic approach , amyloid β , intensive care medicine , neuroscience , psychology , immunology , immune system , toxicity , insulin , insulin resistance
Despite the apparent neurotoxicity of amyloid-β (Aβ), recent clinical trials of Aβ immunotherapy have not shown any clinical benefit in Alzheimer's disease (AD). Given this, clarification of the next generation therapeutic strategy in AD is warranted. Hypothetically, adiponectin might be involved in promoting amyloidogenic evolvability in reproduction, which may result in the adiponectin paradox through antagonistic pleiotropy mechanism in aging, leading to AD. Accordingly, preventing the adiponectin paradox by suppressing adiponectin signaling might prove therapeutic in AD.